Active Pharmaceutical Ingredient (API) Market Report Size, Trends & Growth Opportunity, By Business Mode, By Synthesis Type, By Type of Drug, By Application, By Region and forecast till 2027
Report ID : QR1001269 | Industries : Healthcare | Published On :November 2021 | Page Count : 261
Active Pharmaceutical Ingredient (API) Market
Active Pharmaceutical Ingredient (API) term which is refer to the biologically active component of a drug (e.g., tablet, capsule) and is generally composed of numerous components. The API represents the main ingredient. Other ingredients are usually known as excipients. Any mixture of substances proposed to be used in the manufacture of a drug product and that, when used in the production of a drug, becomes an active ingredient in the drug product is the definition of an Active Pharmaceutical Ingredients (API).
Market Drivers
Raised Incidences of Chronic Diseases is the key driving factor as the growing incidences of chronic diseases have risen pointedly in the past few years because of increased exposure to risk factors and enhanced detection of the ailments at their preliminary stages.
Promotion In the Biopharmaceutical Outlook is one of the driving factors of market because of The intensifying approval of biopharmaceuticals is projected to play out in favour of the active pharmaceutical ingredient industry in the coming period.
Know more about this report: request for sample pages
Upsurge In Novel Drug Applications is also a market driving factor as the progress in reduced new drug applications (ANDA) is showing a sudden spike due to improved funding into the R&D part for treatment of the disease.
Market Restraints
The difficult supervisory strategies and hostile drug price control strategies throughout several countries are likely to limit the development of the active pharmaceutical ingredients' companies. A shift to digital manufacturing and patents for blockbuster drugs is estimated to lower the market's development, so regulatory drawbacks are main restraining factor of the market. The high manufacturing cost of Active Pharmaceutical Ingredient (API) is also one of the main challenges faced by market players.
Market Segmentation
The Global Active Pharmaceutical Ingredients (API) Market is classified in to Business Mode, Synthesis Type, Type of Drug, Application and Geography.
On the basis of Business Mode, it is segmented in to Captive API & Merchant API. On the basis of Synthesis Type it is divided in to Synthetic and Biotech. Further, on the basis of Type of Drug it is segmented in to Generic drug and Branded drug. On the basis of Application market is divided in to seven applications that is Cardiology, Pulmonology, Oncology, Ophthalmology, Neurology, Orthopedic, Other Applications. On the basis of regional analysis, the Global Active Pharmaceutical Ingredients (API) Market is classified into North America, Latin America, Europe, Asia Pacific, and Middle East & Africa.
Regional Analysis
North America accounted for the highest share of the active pharmaceutical ingredients market in 2019, because of the growing occurrence of preventable chronic diseases, increasing government focus on generic drugs, and technological advancements in the manufacturing processes of APIs. The European regional active pharmaceutical ingredient market is the second major market that hold the key share of the market over the forecast period. The Asia Pacific active pharmaceutical ingredient market is estimated to be the fastest growing region in the worldwide active pharmaceutical ingredient market because of the commonness of quickly rising markets (India, China, South Korea) are developing as main hubs for outsourcing drug manufacturing.
Market Key Players
Some of the key operating players are Aurobindo Pharma Limited, Sun Pharmaceutical Industries Ltd., Dr. Reddy’s Laboratories Ltd., Boehringer Ingelheim International GmbH, Cipla, Inc., F. Hoffmann-La Roche AG, Pfizer Inc., Merck & Co., Teva Pharmaceutical Industries Ltd.
Industry development
- In 2020, Pfizer (US) signed a multiyear agreement with Gilead Sciences to manufacture and supply Gilead’s antiviral drug (Remdesivir) for the treatment of COVID-19.
- In April 2020, Boehringer Ingelheim (Germany) acquired Northern Biologics, which focuses on therapeutic antibodies targeting the tumor microenvironment. This acquisition broadened Boehringer Ingelheim’s oncology product portfolio.
- Dec 2020 Piramal is planning to invest USD 32 million into its manufacturing plant in Michigan, US shoring up production and expansion for non-potent and potent active pharmaceutical ingredients (APIs) over the coming two years. The additional 25,000-square-foot expansion will enhance the 8,500 square feet of production area. It's also anticipated to lift volume for large-scale production because novel reactors can process projects up to 4,000 liters, boosting API production from 30% to 40%.
- Dec 2020 Piramal is planning to invest USD 32 million into its manufacturing plant in Michigan, US shoring up production and expansion for non-potent and potent active pharmaceutical ingredients (APIs) over the coming two years. The additional 25,000-square-foot expansion will enhance the 8,500 square feet of production area. It's also anticipated to lift volume for large-scale production because novel reactors can process projects up to 4,000 liters, boosting API production from 30% to 40%.
Active Pharmaceutical Ingredient (API) Market TOC
1 Introduction
1.1 Objective of the Study
1.2 Market definition
1.3 Market Scope
2 Research Methodology
2.1 Data Mining
2.2 Validation
2.3 Primary Interviews
2.4 List of Data Sources
3 Executive Summary
4 Active Pharmaceutical Ingredient (API) Market Outlook
4.1 Overview
4.2 Market Dynamics
4.2.1 Drivers
4.2.2 Restraints
4.2.3 Opportunities
4.3 Porters Five Force Model
4.4 Value Chain Analysis
5 Active Pharmaceutical Ingredient (API) Market, By Business Mode
5.1 Y-o-Y Growth Comparison, By Business Mode
5.2 Active Pharmaceutical Ingredient (API) Market Share Analysis, By Business Mode
5.3 Active Pharmaceutical Ingredient (API) Market Size and Forecast, By Business Mode
5.3.1 Captive API
5.3.2 Merchant API
6 Active Pharmaceutical Ingredient (API) Market, By Synthesis Type
6.1 Y-o-Y Growth Comparison, By Synthesis Type
6.2 Active Pharmaceutical Ingredient (API) Market Share Analysis, By Synthesis Type
6.3 Active Pharmaceutical Ingredient (API) Market Size and Forecast, By Synthesis Type
6.3.1 Synthetic
6.3.2 Biotech
7 Active Pharmaceutical Ingredient (API) Market, By Type of Drug
7.1 Y-o-Y Growth Comparison, By Type of Drug
7.2 Active Pharmaceutical Ingredient (API) Market Share Analysis, By Type of Drug
7.3 Active Pharmaceutical Ingredient (API) Market Size and Forecast, By Type of Drug
7.3.1 Generic
7.3.2 Branded
8 Active Pharmaceutical Ingredient (API) Market, By Application
8.1 Y-o-Y Growth Comparison, By Application
8.2 Active Pharmaceutical Ingredient (API) Market Share Analysis, By Application
8.3 Active Pharmaceutical Ingredient (API) Market Size and Forecast, By Application
8.3.1 Cardiology
8.3.2 Pulmonology
8.3.3 Oncology
8.3.4 Ophthalmology
8.3.5 Neurology
8.3.6 Orthopedic
8.3.7 Other Applications
9 Active Pharmaceutical Ingredient (API) Market, By Region
9.1 Active Pharmaceutical Ingredient (API) Market Share Analysis, By Region
9.2 Active Pharmaceutical Ingredient (API) Market Share Analysis, By Region
9.3 Active Pharmaceutical Ingredient (API) Market Size and Forecast, By Region
10 North America Active Pharmaceutical Ingredient (API) Market Analysis and Forecast (2021-2027)
10.1 Introduction
10.2 North America Active Pharmaceutical Ingredient (API) Market Share Analysis, By Business Mode
10.3 North America Active Pharmaceutical Ingredient (API) Market Size and Forecast, By Synthesis Type
10.4 North America Active Pharmaceutical Ingredient (API) Market Size and Forecast, By Type of Drug
10.4 North America Active Pharmaceutical Ingredient (API) Market Size and Forecast, By Application
10.5 North America Active Pharmaceutical Ingredient (API) Market Size and Forecast, By Country
10.5.1 U.S.
10.5.2 Canada
10.5.3 Mexico
11 Europe Active Pharmaceutical Ingredient (API) Market Analysis and Forecast (2021-2027)
11.1 Introduction
11.2 Europe Active Pharmaceutical Ingredient (API) Market Share Analysis, By Business Mode
11.3 Europe Active Pharmaceutical Ingredient (API) Market Size and Forecast, By Synthesis Type
11.4 Europe Active Pharmaceutical Ingredient (API) Market Size and Forecast, By Type of Drug
11.4 Europe Active Pharmaceutical Ingredient (API) Market Size and Forecast, By Application
11.5 Europe Active Pharmaceutical Ingredient (API) Market Size and Forecast, By Country
11.5.1 Germany
11.5.2 France
11.5.3 UK
11.54. Rest of Europe
12 Asia Pacific Active Pharmaceutical Ingredient (API) Market Analysis and Forecast (2021-2027)
12.1 Introduction
12.2 Asia Pacific Active Pharmaceutical Ingredient (API) Market Share Analysis, By Business Mode
12.3 Asia Pacific Active Pharmaceutical Ingredient (API) Market Size and Forecast, By Synthesis Type
12.4 Asia Pacific Active Pharmaceutical Ingredient (API) Market Size and Forecast, By Type of Drug
12.4 Asia Pacific Active Pharmaceutical Ingredient (API) Market Size and Forecast, By Application
12.5 Asia Pacific Active Pharmaceutical Ingredient (API) Market Size and Forecast, By Country
12.5.1 China
12.5.2 Japan
12.5.3 India
12.5.4. Rest of Asia Pacific
13 Latin America Active Pharmaceutical Ingredient (API) Market Analysis and Forecast (2021-2027)
13.1 Introduction
13.2 Latin America Active Pharmaceutical Ingredient (API) Market Share Analysis, By Business Mode
13.3 Latin America Active Pharmaceutical Ingredient (API) Market Size and Forecast, By Synthesis Type
13.4 Latin America Active Pharmaceutical Ingredient (API) Market Size and Forecast, By Type of Drug
13.4 Latin America Active Pharmaceutical Ingredient (API) Market Size and Forecast, By Application
13.5 Latin America Active Pharmaceutical Ingredient (API) Market Size and Forecast, Country
13.5.1. Brazil
13.5.2. Rest of Latin America
14 Middle East Active Pharmaceutical Ingredient (API) Market Analysis and Forecast (2021-2027)
14.1 Introduction
14.2 Middle East Active Pharmaceutical Ingredient (API) Market Share Analysis, By Business Mode
14.3 Middle East Active Pharmaceutical Ingredient (API) Market Size and Forecast, By Synthesis Type
14.4 Middle East Active Pharmaceutical Ingredient (API) Market Size and Forecast, By Type of Drug
14.4 Middle East Active Pharmaceutical Ingredient (API) Market Size and Forecast, By Application
14.5 Middle East Active Pharmaceutical Ingredient (API) Market Size and Forecast, By Country
14.5.1. Saudi Arabia
14.5.2. UAE
14.5.3. Egypt
14.5.4. Kuwait
14.5.5. South Africa
15 Competitive Analysis
15.1 Competition Dashboard
15.2 Market share Analysis of Top Vendors
15.3 Key Development Strategies
16 Company Profiles
16.1 Aurobindo Pharma Limited
16.1.1 Overview
16.1.2 Offerings
16.1.3 Key Financials
16.1.4 Business Segment & Geographic Overview
16.1.5 Key Market Developments
16.1.6 Key Strategies
16.2 Sun Pharmaceutical Industries Ltd.
16.2.1 Overview
16.2.2 Offerings
16.2.3 Key Financials
16.2.4 Business Segment & Geographic Overview
16.2.5 Key Market Developments
16.2.6 Key Strategies
16.3 Dr. Reddy’s Laboratories Ltd.
16.3.1 Overview
16.3.2 Offerings
16.3.3 Key Financials
16.3.4 Business Segment & Geographic Overview
16.3.5 Key Market Developments
16.3.6 Key Strategies
16.4 Boehringer Ingelheim International GmbH
16.4.1 Overview
16.4.2 Offerings
16.4.3 Key Financials
16.4.4 Business Segment & Geographic Overview
16.4.5 Key Market Developments
16.4.6 Key Strategies
16.5 Cipla Inc.
16.5.1 Overview
16.5.2 Offerings
16.5.3 Key Financials
16.5.4 Business Segment & Geographic Overview
16.5.5 Key Market Developments
16.5.6 Key Strategies
16.6 F. Hoffmann-La Roche AG
16.6.1 Overview
16.6.2 Offerings
16.6.3 Key Financials
16.6.4 Business Segment & Geographic Overview
16.6.5 Key Market Developments
16.6.6 Key Strategies
16.7 Pfizer Inc.
16.7.1 Overview
16.7.2 Offerings
16.7.3 Key Financials
16.7.4 Business Segment & Geographic Overview
16.7.5 Key Market Developments
16.7.6 Key Strategies
16.8 Merck & Co.
16.8.1 Overview
16.8.2 Offerings
16.8.3 Key Financials
16.8.4 Business Segment & Geographic Overview
16.8.5 Key Market Developments
16.8.6 Key Strategies
16.9 Teva Pharmaceutical Industries Ltd.
16.9.1 Overview
16.9.2 Offerings
16.9.3 Key Financials
16.9.4 Business Segment & Geographic Overview
16.9.5 Key Market Developments
16.9.6 Key Strategies